72909 Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment
Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB80
DOI: 10.1016/j.jaad.2026.04.331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Christopher E.M. Griffiths und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Griffiths, C. E., Costanzo, A., Papp, K. A., Rosmarin, D., Puig, L., Blauvelt, A., Wixted, K., Pinto, J. M. L., Lambert, J., Warham, R., & Han, G. (2026). 72909 Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment. Journal of the American Academy of Dermatology, 95(1), AB80. https://doi.org/10.1016/j.jaad.2026.04.331
Vancouver
Griffiths CE, Costanzo A, Papp KA, Rosmarin D, Puig L, Blauvelt A, et al. 72909 Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment. Journal of the American Academy of Dermatology. 2026;95(1):AB80. doi:10.1016/j.jaad.2026.04.331
BibTeX
@article{Griffiths2026,
author = {Griffiths, Christopher E.M. and Costanzo, Antonio and Papp, Kim A. and Rosmarin, David and Puig, Luis and Blauvelt, Andrew and Wixted, Krista and Pinto, José M. López and Lambert, Jérémy and Warham, Rhys and Han, George},
title = {72909 Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {1},
pages = {AB80},
doi = {10.1016/j.jaad.2026.04.331}
}
EUVIMED